Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 12

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 12
---
 exchange for up to 2,666,600 of the Company's common shares or certain cash consideration pursuant to a "tag offer". In addition to resale restrictions prescribed under applicable securities law, common shares issued to Antev Vendors will be subject to a staggered lock-up and an agreement granting certain voting rights in favor of management of the Company for 36 months. Upon the achievement of certain milestones related to potential future FDA Phase 2 and New Drug Administration approvals, as more particularly described in the Definitive Agreement, the Antev Vendors will be entitled to receive up to approximately $65 million in additional contingent consideration. This prospectus is part of the registration statement filed on Form S-1 pursuant to the Definitive Agreement to register for resale by the Selling Shareholders of certain of the Consideration Shares from time to time. The foregoing description of the Definitive Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Definitive Agreement, which is filed as Exhibit 2.4 hereto and is incorporated herein by reference.

The Antev Transaction was completed on August 29, 2025, with the Company acquiring 98.6% of the Antev shares for aggregate consideration consisting of approximately $2.97 million in cash and 1,603,164 common shares of the Company. Pursuant to the Antev Transaction, the Company is now developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first AUR episodes due to enlarged prostate. Teverelix is a long-acting GnRH antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. No assurances can be made that we will successfully integrate Antev into our business and operations or successfully develop Teverelix.

See "Risk Factors-We may not successfully integrate Antev into our business and operations or successfully develop Teverelix."

Warrant Inducement Agreement

On July 14, 2025, we entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. ("Armistice") (the "Warrant Inducement Agreement"), pursuant to which Armistice agreed to exercise existing warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10